Back to today’s briefing

Story perspectives

Study Reveals Promising Drugs for Reversing Liver Disease

10/17/2025

50 4

Summary

Story summary

A study suggests that pemafibrate and telmisartan may reverse metabolic dysfunction-associated steatotic liver disease (MASLD) in animal models.
MASLD affects nearly 40% of adults worldwide.
The drugs significantly reduce fat accumulation in the liver in animal models.
The study was published in Pharmacological Research.
Researchers say further investigation is needed to confirm the findings and assess repurposing.

1 of 1

Story summary

A study suggests that pemafibrate and telmisartan may reverse metabolic dysfunction-associated steatotic liver disease (MASLD) in animal models.
MASLD affects nearly 40% of adults worldwide.
The drugs significantly reduce fat accumulation in the liver in animal models.
The study was published in Pharmacological Research.
Researchers say further investigation is needed to confirm the findings and assess repurposing.